Article
The FDA issued its first approval of a CRISPR gene-editing therapy.
Rating:
0.0
Views:
48
Likes:
1
Library:
1
The US Food and Drug Administration announced the approval of two gene-based therapies for sickle cell disease, one of which uses the genome editing technology CRISPR. It's a big milestone, but access to the therapies for now will still be very limited and expensive, the New York Times explains.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value